NasdaqCM:XBIO

Stock Analysis Report

Executive Summary

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on progressing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($7M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Xenetic Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.9%

XBIO

0.2%

US Biotechs

0.8%

US Market


1 Year Return

-95.6%

XBIO

18.8%

US Biotechs

22.0%

US Market

Return vs Industry: XBIO underperformed the US Biotechs industry which returned 18.8% over the past year.

Return vs Market: XBIO underperformed the US Market which returned 22% over the past year.


Shareholder returns

XBIOIndustryMarket
7 Day-1.9%0.2%0.8%
30 Day22.4%8.2%1.7%
90 Day-17.1%15.5%5.2%
1 Year-95.6%-95.6%19.9%18.8%24.7%22.0%
3 Year-96.9%-96.9%27.8%23.6%46.9%37.3%
5 Year-98.1%-98.1%3.8%-1.3%65.5%47.3%

Price Volatility Vs. Market

How volatile is Xenetic Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xenetic Biosciences undervalued compared to its fair value and its price relative to the market?

0.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XBIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XBIO is good value based on its PB Ratio (0.4x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Xenetic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Xenetic Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Xenetic Biosciences performed over the past 5 years?

13.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XBIO is currently unprofitable.

Growing Profit Margin: XBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare XBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: XBIO has a negative Return on Equity (-72.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Xenetic Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: XBIO's short term assets ($12.9M) exceed its short term liabilities ($1.7M).

Long Term Liabilities: XBIO's short term assets ($12.9M) exceed its long term liabilities ($2.9M).


Debt to Equity History and Analysis

Debt Level: XBIO is debt free.

Reducing Debt: XBIO has no debt compared to 5 years ago when its debt to equity ratio was 2.8%.


Balance Sheet

Inventory Level: XBIO has a low level of unsold assets or inventory.

Debt Coverage by Assets: XBIO's debt is not covered by short term assets (assets are -2091.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XBIO has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 15.7% each year


Next Steps

Dividend

What is Xenetic Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate XBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Xenetic Biosciences's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Jeff Eisenberg (53yo)

2.2yrs

Tenure

US$318,333

Compensation

Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also served as a  ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD318.33K) is below average for companies of similar size in the US market ($USD528.59K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.7yrs

Average Tenure

54yo

Average Age

Experienced Management: XBIO's management team is considered experienced (2.7 years average tenure).


Board Age and Tenure

2.3yrs

Average Tenure

63yo

Average Age

Experienced Board: XBIO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114.7%.


Management Team

  • Jeff Eisenberg (53yo)

    CEO & Director

    • Tenure: 2.2yrs
    • Compensation: US$318.33k
  • Jim Parslow (54yo)

    CFO, COO & Corporate Secretary

    • Tenure: 2.7yrs
    • Compensation: US$287.60k
  • Curt Lockshin (59yo)

    Chief Scientific Officer

    • Tenure: 2.9yrs
    • Compensation: US$259.58k

Board Members

  • Jeff Eisenberg (53yo)

    CEO & Director

    • Tenure: 2.2yrs
    • Compensation: US$318.33k
  • Adam Logal (41yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$115.64k
  • Roger Kornberg (72yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$115.64k
  • Firdaus Dastoor (66yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$115.64k
  • Jim Callaway (62yo)

    Independent Director

    • Tenure: 2.3yrs
    • Compensation: US$115.64k
  • Dmitry Genkin (52yo)

    Director

    • Tenure: 2.3yrs
  • Alexander Gabibov (64yo)

    Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Matthew Frigault

    Member of Scientific Advisory Board

    • Tenure: 0.9yrs
  • Franco Cavalli (77yo)

    Member of Scientific Advisory Board

    • Tenure: 0.9yrs
  • Davide Rossi

    Member of Scientific Advisory Board

    • Tenure: 0.9yrs

Company Information

Xenetic Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xenetic Biosciences, Inc.
  • Ticker: XBIO
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.395m
  • Shares outstanding: 5.76m
  • Website: https://www.xeneticbio.com

Number of Employees


Location

  • Xenetic Biosciences, Inc.
  • 40 Speen Street
  • Suite 102
  • Framingham
  • Greater London
  • 1701
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XBIONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2014

Biography

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on progressing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/16 00:42
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.